Efficacy of combination of transarterial chemoembolization and radiation therapy for patients with hepatocellular carcinoma ineligible for resection or radiofrequency ablation.

• Material Type: 博士論文
• Title: Efficacy of combination of transarterial chemoembolization and radiation therapy for patients with hepatocellular carcinoma ineligible for resection or radiofrequency ablation.
• Author/Editor: Inoue, Masayoshi; Takahama, Junko; Kunichika, Hideki; Shimoda, Emiko; Morimoto, Kengo; Nikimoto, Mei; Inooka, Nobuyoshi; Hasegawa, Masatoshi
• Author Heading: Inoue, Masayoshi; Takahama, Junko; Kunichika, Hideki; Shimoda, Emiko; Morimoto, Kengo; Nikimoto, Mei; Inooka, Nobuyoshi; Hasegawa, Masatoshi
• Publication, Distribution, etc.: 奈良医学会
• Publication Date: 2022
• Publication Date (W3CDTF): 2022
• Alternative Title: 切除およびラジオ波凝固療法が適応外と判断された肝細胞癌症例に対する経動脈的化学塞栓療法と放射線療法の併用療法の効果
• Periodical title: Journal of Nara Medical Association
• No. or year of volume/issue: 73 1,2,3
• Volume: 73
• Issue: 1,2,3
• Pages: 1-9
• ISSN (Periodical Title): ISSN : 1345-0069
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2022-03-15
• Dissertation Number: 甲第837号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: hepatocellular carcinoma; radiation therapy; stereotactic body radiotherapy; trans-arterial chemoembolization; radiofrequency ablation; treatment outcome
• Target Audience: 一般
• Note (General): type:Thesis; Purpose: The local control rate of trans-arterial chemoembolization (TACE) for the patients with hepatocellular carcinoma (HCC) was unsatisfactory compared to resection or radiofrequency ablation (RFA). We performed radiation therapy after TACE to increase the control rate in our institution. The purpose of this study was to evaluate the efficacy and toxicity of the TACE and radiotherapy combination in HCC patients ineligible for resection or RFA. Material and Methods: Between January 2017 and April 2020, 33 patients with HCC ineligible for resection or RFA were treated with a combination of TACE and radiation therapy. Eight patients were initial cases, and 25 were recurrent or residual cases. A total dose of 40-60 Gy in 5-20 fractions was delivered to the 50-90% isodose line. Results: The median follow-up period was 16 months (range, 6-47 months); objective response rate, 66.7%; and the 1- and 2-year overall survival rates, 72.7% and 62.5%, respectively. The objective response rate of HCCs <5 cm was 79.2%; the 1- and 2-year overall survival rates, 91.7% and 62.5%, respectively; median progression-free survival, 13.5 months (range, 3-47 months), and the 1- and 2-year local progression-free survival rates, 95.8% and 85.7%, respectively. There was one case each of grade 2 radiation esophagitis and ascites after three months of irradiation. Conclusion: The combination of TACE and radiation therapy shows good local control and acceptable toxicity, particularly in HCCs <5 cm and may be a good treatment option.; 博士（医学）・甲第837号・令和4年3月15日; identifier:Journal of Nara Medical Association Vol.73 No.1,2,3 p.01-09 (2022.06); identifier:13450069; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/4020; identifier:Journal of Nara Medical Association, 73(1,2,3): 1-9
• Access Restrictions: インターネット公開
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

Table of Contents

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4020/1/01%e7%94%b2837%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4020/2/02%e7%94%b2837%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4020/8/03%e7%94%b2837%e6%9c%ac%e6%96%87.pdf fulltext